Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER: Interferon-beta Efficacy Recovery in RRMS
NCT00492466Phase 4Completed
- Sponsor
- Biogen
- Start
- Mar 2003
- Primary completion
- Aug 2006
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Reduction in the proportion of patients being neutralizing antibody (NAb) positive at 15 months. Started Mar 2003; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00492466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492466.